See the DrugPatentWatch profile for Onivyde
Information regarding a blog specifically about Onivyde is not available in the provided context.
What is Onivyde?
Onivyde is an FDA-approved treatment for pancreatic cancer. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1].
How is Onivyde administered?
Onivyde is administered intravenously [1].
What is Onivyde used to treat?
Onivyde is indicated for patients with metastatic adenocarcinoma of the pancreas whose disease has progressed following gemcitabine-based therapy [1].
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and pyrexia [1]. Severe side effects can include neutropenia, febrile neutropenia, and severe diarrhea [1].
What is the mechanism of action for Onivyde?
Onivyde works by inhibiting topoisomerase I, an enzyme that helps relieve torsional strain in DNA during replication and transcription. By interfering with this enzyme, Onivyde causes DNA strand breaks, ultimately leading to cancer cell death [1].
What is the current patent status for Onivyde?
Information on the specific patent status and expiry dates for Onivyde is not detailed in the provided context. For detailed patent information, resources like DrugPatentWatch.com may offer further insights [2].
Sources:
[1] https://www.onivyde.com/
[2] https://drugpatentwatch.com/